Noor Naffakh

ORCID: 0000-0001-5195-8313
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Artificial Intelligence in Healthcare and Education
  • Venous Thromboembolism Diagnosis and Management
  • Childhood Cancer Survivors' Quality of Life
  • Intramuscular injections and effects
  • Heparin-Induced Thrombocytopenia and Thrombosis
  • Radiomics and Machine Learning in Medical Imaging
  • Acute Lymphoblastic Leukemia research
  • Adolescent and Pediatric Healthcare
  • Bone health and treatments
  • Histone Deacetylase Inhibitors Research
  • Management of metastatic bone disease
  • AI in cancer detection
  • Cancer Diagnosis and Treatment
  • Acute Myeloid Leukemia Research
  • Anesthesia and Sedative Agents
  • Healthcare Technology and Patient Monitoring
  • Respiratory Support and Mechanisms
  • Cancer Treatment and Pharmacology

University of Illinois Chicago
2023-2025

University of Illinois Urbana-Champaign
2024

Saint Francis Medical Center
2022

54 Background: While the standard dose of AA (1,000 mg) is taken on an empty stomach, low-dose (250 mg with a low-fat meal) also option, both listed as care in national guidelines for treatment prostate cancer (PCa). We sought to evaluate cost and adherence (LDAA) versus standard-dose (SDAA) diverse population treated at University Illinois Chicago (UIC), safety-net hospital. Methods: PCa patients UIC who filled least oneprescription between April 2017 September 2024 were identified...

10.1200/jco.2025.43.5_suppl.54 article EN Journal of Clinical Oncology 2025-02-10

Abstract Background: The Precision Oncology Tumor Board (POTB) at the University of Illinois Chicago (UIC) advances cancer treatment through molecular profiling and personalized recommendations. Studies link tumor boards to improved outcomes. POTB integrates multidisciplinary expertise across institutions provide therapeutic trial recommendations based on clinical genomic data. PROMOTE (PRecision Oncology: Measuring Outcomes Treatment Effectiveness) study is a retrospective analysis cases...

10.1158/1538-7445.am2025-3381 article EN Cancer Research 2025-04-21

1555 Background: Next-generation sequencing (NGS) is a routine clinical practice in advanced NSCLC. NGS reports are information-dense and interpretation remains challenge. ChatGPT large language model (LLM) AI chatbot that can generate text response to user-generated prompts. We sought assess the relevance accuracy of ChatGPT-generated with first-line (1L) treatment recommendations for NSCLC patients targetable driver oncogenes. Methods: Eight oncogenes FDA-approved targeted 1L stage IV were...

10.1200/jco.2023.41.16_suppl.1555 article EN Journal of Clinical Oncology 2023-06-01

Precision oncology in non-small cell lung cancer (NSCLC) relies on biomarker testing for clinical decision making. Despite its importance, challenges like the lack of genomic training, nonstandardized reporting, and a rapidly evolving treatment landscape hinder practice. Generative artificial intelligence (AI), such as ChatGPT, offers promise enhancing support. Effective performance metrics are crucial to evaluate these models' accuracy their propensity producing incorrect or hallucinated...

10.1200/cci.24.00123 article EN JCO Clinical Cancer Informatics 2024-12-01

Heparin-induced skin necrosis (HISN) is a rare complication of heparin anticoagulation. The condition occurs in various situations, including heparin-naive and exposed individuals, areas local or distant from the injection site, with without frank thrombocytopenia. We present case which patient treated for pulmonary embolism therapeutic unfractionated (UFH) develops this adverse event. Symptoms were reversed cessation UFH transition to bivalirudin surgical debridement. initially had anti-PF4...

10.1097/mbc.0000000000001112 article EN Blood Coagulation & Fibrinolysis 2022-01-10

e19074 Background: Hypomethylating agents (HMA) such as decitabine and azacitidine are frontline therapies for myelodysplastic syndrome (MDS) acute myeloid leukemia (AML). Limited data exist on subsequent cardiovascular (CV) events. Johnson et al. reported 170 patients receiving HMA + venetoclax with a CV event rate of 20%. Aims: To investigate the incidence events in HMA. Methods: We analyzed adult AML MDS > 1 dose or from 1/2018-12/2020. New were defined new atrial fibrillation,...

10.1200/jco.2023.41.16_suppl.e19074 article EN Journal of Clinical Oncology 2023-06-01
Coming Soon ...